UNICYCIVE THERAPEUTICS, INC. (UNCY) Current Ratio
- Current ratio · latest quarter: Value 3.81×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.81× | Current assets / current liabilities. $71.32M ÷ $18.70M ≈ 3.81× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 71.32M USD | Assets, Current |
| Current obligations | 18.70M USD | Liabilities, Current |
| Cash and equivalents | 44.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 17.24M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | Inventory, Net |
| Payables | 2.23M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $71.32M | $18.70M | $44.19M | $17.24M | (m) | (m) | $2.23M | (m) | 3.81× |
| 2026-03-31 | $63.55M | $26.48M | $37.37M | $17.21M | (m) | (m) | $1.14M | (m) | 2.40× |
| 2025-12-31 | $48.96M | $18.94M | $29.20M | $12.07M | (m) | (m) | $383.00K | (m) | 2.59× |
| 2025-09-30 | $50.29M | $13.13M | $42.70M | (m) | (m) | (m) | $957.00K | (m) | 3.83× |
| 2025-06-30 | $29.53M | $13.57M | $22.33M | (m) | (m) | (m) | $775.00K | (m) | 2.18× |
| 2025-03-31 | $27.35M | $16.68M | $19.77M | (m) | (m) | (m) | $1.40M | (m) | 1.64× |
| 2024-12-31 | $30.95M | $24.12M | $26.14M | (m) | (m) | (m) | $1.06M | (m) | 1.28× |
| 2024-09-30 | $37.74M | $10.46M | (m) | (m) | (m) | (m) | $548.00K | (m) | 3.61× |
| 2024-06-30 | $44.05M | $13.09M | (m) | (m) | (m) | (m) | $1.47M | (m) | 3.37× |
| 2024-03-31 | $51.68M | $30.28M | (m) | (m) | (m) | (m) | $1.24M | (m) | 1.71× |
| 2023-12-31 | $13.40M | $17.53M | (m) | (m) | (m) | (m) | $839.00K | (m) | 0.76× |
| 2023-09-30 | $18.57M | $15.46M | $14.35M | (m) | (m) | (m) | $1.08M | (m) | 1.20× |
| 2023-06-30 | $21.93M | $15.42M | $18.82M | (m) | (m) | $3.11M | $503.00K | (m) | 1.42× |
| 2023-03-31 | $26.18M | $15.97M | $24.33M | (m) | (m) | $1.85M | $790.00K | (m) | 1.64× |
| 2022-12-31 | $2.64M | $3.28M | (m) | (m) | (m) | (m) | $892.00K | (m) | 0.81× |
| 2022-09-30 | $9.96M | $5.52M | $7.01M | (m) | (m) | $2.95M | $2.29M | (m) | 1.80× |
| 2022-06-30 | $12.56M | $2.83M | $10.57M | (m) | (m) | $1.99M | $747.00K | (m) | 4.43× |
| 2022-03-31 | $15.46M | $2.40M | $13.62M | (m) | (m) | $1.84M | $589.00K | (m) | 6.44× |
| 2021-12-31 | $18.41M | $2.10M | $16.58M | (m) | (m) | $1.83M | $742.00K | (m) | 8.75× |
| 2021-09-30 | $19.78M | $785.00K | $18.01M | (m) | (m) | (m) | $49.00K | (m) | 25.20× |
| 2021-06-30 | $913.00K | $5.12M | $1.00K | (m) | (m) | (m) | $357.00K | (m) | 0.18× |
| 2020-12-31 | $204.00K | $2.88M | (m) | (m) | (m) | (m) | $184.00K | (m) | 0.07× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |